COMPASS Pathways (NASDAQ:CMPS) Trading 4.6% Higher

COMPASS Pathways plc (NASDAQ:CMPS - Get Free Report) rose 4.6% during mid-day trading on Tuesday . The company traded as high as $8.73 and last traded at $8.70. Approximately 317,074 shares changed hands during trading, a decline of 55% from the average daily volume of 701,797 shares. The stock had previously closed at $8.32.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $120.00 price objective on shares of COMPASS Pathways in a research report on Friday, March 1st. Morgan Stanley assumed coverage on COMPASS Pathways in a research report on Monday, April 1st. They issued an "overweight" rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and an average price target of $47.40.

COMPASS Pathways Trading Up 5.5 %

The company has a debt-to-equity ratio of 0.14, a quick ratio of 13.33 and a current ratio of 13.33. The business has a fifty day simple moving average of $10.07 and a 200 day simple moving average of $8.34. The stock has a market capitalization of $543.83 million, a price-to-earnings ratio of -3.67 and a beta of 2.48.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last released its earnings results on Thursday, February 29th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.16). As a group, research analysts expect that COMPASS Pathways plc will post -2.4 EPS for the current year.

Insider Buying and Selling

In other news, Director George Jay Goldsmith sold 20,205 shares of the firm's stock in a transaction dated Friday, January 19th. The stock was sold at an average price of $7.99, for a total transaction of $161,437.95. Following the completion of the transaction, the director now directly owns 4,198,154 shares in the company, valued at $33,543,250.46. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other COMPASS Pathways news, Director George Jay Goldsmith sold 20,205 shares of the company's stock in a transaction on Friday, January 19th. The shares were sold at an average price of $7.99, for a total transaction of $161,437.95. Following the sale, the director now owns 4,198,154 shares of the company's stock, valued at $33,543,250.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Ekaterina Malievskaia sold 19,853 shares of the company's stock in a transaction on Tuesday, February 6th. The shares were sold at an average price of $10.59, for a total transaction of $210,243.27. Following the sale, the director now directly owns 4,144,994 shares in the company, valued at approximately $43,895,486.46. The disclosure for this sale can be found here. Insiders sold a total of 162,675 shares of company stock valued at $1,511,656 in the last three months. Insiders own 23.99% of the company's stock.

Hedge Funds Weigh In On COMPASS Pathways

Institutional investors and hedge funds have recently made changes to their positions in the stock. Quantbot Technologies LP raised its holdings in shares of COMPASS Pathways by 156.8% in the 1st quarter. Quantbot Technologies LP now owns 3,338 shares of the company's stock worth $43,000 after acquiring an additional 2,038 shares during the last quarter. Quest Partners LLC acquired a new stake in shares of COMPASS Pathways in the 4th quarter worth about $33,000. UBS Group AG raised its holdings in shares of COMPASS Pathways by 249.1% in the 4th quarter. UBS Group AG now owns 4,291 shares of the company's stock worth $34,000 after acquiring an additional 3,062 shares during the last quarter. Advisor Group Holdings Inc. raised its holdings in shares of COMPASS Pathways by 129.7% in the 4th quarter. Advisor Group Holdings Inc. now owns 5,406 shares of the company's stock worth $43,000 after acquiring an additional 3,052 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of COMPASS Pathways by 229.6% in the 3rd quarter. Tower Research Capital LLC TRC now owns 7,847 shares of the company's stock worth $58,000 after acquiring an additional 5,466 shares during the last quarter. Institutional investors own 46.19% of the company's stock.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.